sur Piramal Pharma Limited
Piramal Pharma Reports FY2026 Achievements in Annual Report
Piramal Pharma Limited (PPL) has released its FY2026 Annual Report, highlighting its global growth and commitment to innovation and sustainability. The company reported a revenue of ₹8,869 crore, with 66% stemming from regulated markets, underpinning its substantial global presence.
Piramal Pharma Solutions contributed significantly, accounting for 55% of revenues and reinforcing its position within the global CDMO sector. Piramal Critical Care maintained its lead in the US inhaled anesthesia market. Meanwhile, Piramal Consumer Healthcare generated ₹1,274 crore, launching 31 new products and achieving 24% growth in power brands.
The company completed 38 regulatory inspections without receiving any Official Action Indicated (OAI) observations, highlighting its commitment to quality. Sustainability efforts include a 22.6% reduction in greenhouse gas emissions. The company expanded its workforce to over 7,285 employees while ensuring workplace safety with zero fatalities for five consecutive years.
R. P.
Copyright © 2026 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de Piramal Pharma Limited